Xvivo Perfusion (XVIVO.ST) traded down -1.84 % during a 24 hours period ending at 11:50 PM Central Europe on Tuesday 27th. One Xvivo Perfusion stock can currently be bought for about SEK 202 on popular exchanges. Current supply of Xvivo Perfusion stocks is 31.4 mn. Xvivo Perfusion has a current market capitalization of SEK 6.4 bn and approximately SEK 21.4 mn worth of Xvivo Perfusion was traded on exchanges in the last 24 hours. Since last month end, Xvivo Perfusion has traded -15.04 % down. Simple moving average of last 200 days is at SEK 244.07. The highest price of past 52 weeks was recorded at SEK 314.8 on 08/11/2026. 52 weeks low was at SEK 160.1 on 11/18/2025.

Summary of the latest news for Xvivo Perfusion

In a recent Trading Direkt Healthcare broadcast, several medical‑technology companies were discussed, including Xvivo Perfusion AB. The Swedish company’s chief executive highlighted potential growth opportunities in the United States over the coming year, noting that 2027 could serve as a launchpad for new technologies. While no specific financial figures were released, the remarks suggest optimism about the firm’s expansion prospects and the broader market environment for perfusion equipment.

Here is how related stocks have performed in the past 24 hours:

  • Investment Oresund (ORES.ST) traded up 2.23 % and now trades at SEK 146.6. Current market capitalisation for Investment Oresund is SEK 6.6 bn. Current price/earnings ratio for Investment Oresund is 5.26.

  • Fastpartner (FPAR-A.ST) traded down -1.18 % and now trades at SEK 37.7. Fastpartner has a market capitalisation of SEK 7.4 bn. Current price/earnings ratio for Fastpartner is 20.54.

  • Dometic (DOM.ST) traded down -3.01 % and now trades at SEK 20.02. Dometic has a market capitalisation of SEK 6.5 bn. Pareto Securities has maintained its recommendation for Dometic Group AB while lowering its target price. The Swedish broker noted that the company’s third‑quarter revenue and EBITDA exceeded expectations by modest margins, yet demand outlooks remain subdued. Analysts cited weak market conditions and elevated debt levels as pressure points for the business. Pareto projects modest organic growth in the next year and anticipates an EBITDA margin of just over eleven percent for 2027. The valuation it proposes corresponds to roughly nine times the expected earnings‑before‑interest‑tax‑depreciation for 2026, reflecting a cautious stance toward the company’s near‑term prospects.

  • Bahnhof -B (BAHN-B.ST) traded flat 0 % and now trades at SEK 59.8. Bahnhof -B has a market capitalisation of SEK 6.4 bn. Bahnhof -B has a current price to earnings ratio of 34.48.

  • Sivers Semiconductors (SIVE.ST) traded up 1.94 % and now trades at SEK 22.68. Sivers Semiconductors has a market capitalisation of SEK 7 bn.

About Xvivo Perfusion

Xvivo Perfusion AB is a medical technology company based in Goteborg, Sweden, that specializes in developing optimized solutions for organ, tissue, and cell preservation in connection with transplantation. These solutions are aimed at revolutionizing the current standard of care in the health care industry by providing innovative equipment and supplies for improved patient outcomes.